The new year kick started with a bumper deal in the pharma space, with Bristol-Myers Squibb Co BMY 3.95% agreeing to buy Celgene Corporation CELG 5.58%.
Can the deal infuse some momentum into the space following a down year? Here are some key catalysts of the upcoming week that could provide an answer.
Conferences
- 6th Annual Dermatology Summit – Jan. 6, in San Francisco, California
- Biotech Showcase – Jan. 7-9, in San Francisco
- 37th Annual JPMorgan Healthcare Conference – Jan.7-10, in San Francisco
- 11th Annual T-cell Lymphoma Forum – Jan. 10-12, in La Jolla, California
Clinical Trials
Axsome Therapeutics Inc AXSM 0.75% is due to release Phase 2 data for AXS-05 which is being evaluated in a study dubbed ASCEND for treating major depressive disorder. The release is scheduled for early January.
Miragen Therapeutics Inc MGEN 21.07% will present updated Phase 1 data for Cobomarsen at the 11th annual T-cell Lymphoma Forum at 6 pm PT Jan. 11. Cobomarsen is being evaluated for a variety of blood cancer types such as chronic lymphocytic leukemia, diffuse large B-cell lymphoma and cutaneous T-cell lymphoma.
IPO Quiet Period Expiry
Hong Kong-based pharma company Aptorum Group Ltd APM 0.19% offered 1.9 million shares in an IPO in December, with the offering priced at $15.80. The shares were listed on the Nasdaq Dec. 18 and closed the debut session at $14.35.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.